Literature DB >> 10524244

Developmentally-regulated expression of mNapor encoding an apoptosis-induced ELAV-type RNA binding protein.

D K Choi1, T Ito, F Tsukahara, M Hirai, Y Sakaki.   

Abstract

Proteins with RNA recognition motifs (RRMs) participate in many aspects of RNA metabolism, and some of them are required for the accomplishment of normal development. The neuroblastoma apoptosis-related RNA binding protein (NAPOR) is an ELAV-type RNA-binding protein with three characteristic RNP2/RNP1-type RRMs, which we identified as a gene induced during apoptosis of neuroblastoma cells. Here we isolated and characterized the cDNA for mNapor, the mouse homolog of NAPOR. The mNapor encodes mRNA sharing striking homology with that of NAPOR, not only in its open reading frame (98.5%) but also in the 3'-untranslated region (80.1%), and is mapped to chromosome 2 A2-A3, a region syntenic to the human NAPOR locus. In situ hybridization analysis revealed that the expression pattern of mNapor is spatially and temporally coincident with the occurrence of programmed cell death, suggesting its involvement in the development of the central nervous system in which apoptosis plays a crucial role.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10524244     DOI: 10.1016/s0378-1119(99)00312-1

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  13 in total

Review 1.  The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins.

Authors:  Twishasri Dasgupta; Andrea N Ladd
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-08-17       Impact factor: 9.957

2.  Role of RNA-Binding Proteins in Colorectal Carcinogenesis.

Authors:  Shrikant Anant; Courtney W Houchen; Vaibhav Pawar; Satish Ramalingam
Journal:  Curr Colorectal Cancer Rep       Date:  2010-03-02

3.  Region-specific alternative splicing in the nervous system: implications for regulation by the RNA-binding protein NAPOR.

Authors:  Wenqing Zhang; Haiying Liu; Kyoungha Han; Paula J Grabowski
Journal:  RNA       Date:  2002-05       Impact factor: 4.942

4.  Antagonistic regulation of alpha-actinin alternative splicing by CELF proteins and polypyrimidine tract binding protein.

Authors:  Natalia Gromak; Arianne J Matlin; Thomas A Cooper; Christopher W J Smith
Journal:  RNA       Date:  2003-04       Impact factor: 4.942

Review 5.  CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.

Authors:  Andrea N Ladd
Journal:  Mol Cell Neurosci       Date:  2012-12-14       Impact factor: 4.314

Review 6.  Posttranscriptional regulation of gene networks by GU-rich elements and CELF proteins.

Authors:  Irina A Vlasova; Paul R Bohjanen
Journal:  RNA Biol       Date:  2008-10-23       Impact factor: 4.652

7.  Diversity and conservation of CELF1 and CELF2 RNA and protein expression patterns during embryonic development.

Authors:  Y Blech-Hermoni; S J Stillwagon; A N Ladd
Journal:  Dev Dyn       Date:  2013-04-15       Impact factor: 3.780

8.  Novel intestinal splice variants of RNA-binding protein CUGBP2: isoform-specific effects on mitotic catastrophe.

Authors:  Satish Ramalingam; Gopalan Natarajan; Chris Schafer; Dharmalingam Subramaniam; Randal May; Ilangovan Ramachandran; Lurdes Queimado; Courtney W Houchen; Shrikant Anant
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-02-07       Impact factor: 4.052

9.  Alternative splicing produces structural and functional changes in CUGBP2.

Authors:  Hitoshi Suzuki; Makoto Takeuchi; Ayumu Sugiyama; Ahm Khurshid Alam; Luyen Thi Vu; Yoshiharu Sekiyama; Hieu Chi Dam; Shin-Ya Ohki; Toshifumi Tsukahara
Journal:  BMC Biochem       Date:  2012-03-20       Impact factor: 4.059

10.  The neurofibromatosis type I pre-mRNA is a novel target of CELF protein-mediated splicing regulation.

Authors:  Victoria A Barron; Hui Zhu; Melissa N Hinman; Andrea N Ladd; Hua Lou
Journal:  Nucleic Acids Res       Date:  2009-10-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.